$EDXC CEO Todd Davis Featured on Dr. Ronald Hoffman’s Intelligent Medicine(TM)

In the program, Mr. Davis joins Dr. Daniel Kiddy, podiatrist and CBD researcher, and Dr. Hoffman for a discussion on the medical applications, politics, and legality of Cannabidiol (CBD), a compound that is showing a wide array of health benefits. In multiple clinical studies, CBD has been shown to interact with the body’s endocannabinoid system (ECS) and to possess anti-inflammatory, antioxidant, immune regulatory, analgesic and neuroprotective properties. As a result, cannabidiol can be helpful in the support and treatment of a wide variety of conditions including arthritic pain, insomnia, anxiety, depression, fibromyalgia, multiple sclerosis, inflammatory bowel disease, heart disease, neuropathic pain, headache, migraine, nausea, neurodegenerative diseases like Alzheimer’s and Parkinson’s, and even certain types of cancer. In the broadcast, Dr. Kiddy shares his patients’ experiences from an ongoing study he conducts with his patients; Todd Davis provides an informative overview of the potential applications of CBD and emphasizes the need for ongoing medical research.

To access the full program please visit:https://drhoffman.com/podcast/hemp-based-nutritional-extracts-part-1/

Dr. Ronald Hoffman is a pioneering complementary medicine practitioner, Director of the Hoffman Center for Integrative Medicine based in New York City, and host of the popular and long running syndicated weekly radio program and podcast “Intelligent Medicine.”

About Endexx
Endexx provides innovative medical marijuana management and technology solutions. Endexx, with its collaborative partners and consultants, develops and distributes consumable product lines derived from industrial hemp that is GMO and pesticides free and naturally rich in phytocannabinoids. The company has two technology products and services that launched in 2014 — the M3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through “seed to sale” inventory management and tracking. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to an eventual federal mandates. The Autospense™ is a high-tech marijuana inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailer, while enhancing their service quality by reducing transaction time for customers. Websites include:www.cbdunlimited.com, www.cbdhealthsolutions.com,www.endexx.com, www.m3hub.com.

Safe Harbor Notice

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.